Perspective Therapeutics Enters Clinical Trial Collaboration With Merck To Combine Its PSV359 With Keytruda Under An Amendment To Ongoing Phase 1/2A Study Of PSV359 In Patients With Certain Types Of Non-Small Cell Lung Cancer And Colorectal Cancer
Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
Perspective Therapeutics is testing its cancer medicine with Merck's popular drug Keytruda. This partnership suggests the companies believe combining these treatments might work better for patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.